Advanced Solid Tumor — A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
Citation(s)
A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Cancer Activity of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors